CuraSeal
Regenerating medical technology solutions to restore structure and function of damaged tissues and organs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | $700k | Debt | |
| Total Funding | 000k | ||
Related Content
CuraSeal Inc., founded in 2007 by Harold Carrison, Akshay Mavani, and Kenton Fong, is a medical device company focused on developing regenerative and minimally invasive technologies. The firm operates within the therapeutic devices industry, specifically targeting drug delivery and the treatment of damaged tissues and organs.
The company's core business revolves around creating interventional devices that merge tissue engineering with minimally invasive techniques. CuraSeal is developing solutions for delivering therapeutics like collagen, antimicrobial chemotherapy, growth factors, and cell-based therapies. A key area of development is the treatment of Enterocutaneous and Enteroenteric Fistulas. Their flagship product under development, the CuraSeal PICS™ system, is a minimally invasive healing system designed to reduce the need for long-term intravenous nutrition and extended hospital stays.
Another product line, associated with the brand InCurA, is a plant-based hemostatic powder called Curaseal Complex Starch Nano-in-Microspheres. This product is designed for rapid blood clotting during surgical procedures and is fully absorbed by the body. Its mechanism involves nanoporous, concave microparticles that adhere to a bleeding site, absorb fluid, and swell to apply mechanical pressure, thereby stopping blood flow in seconds. This technology is intended for use in a variety of surgical fields, including vascular, cardiothoracic, orthopedic, and general surgery.
CuraSeal Inc. has a history of venture funding, having raised capital through several rounds, including a Series B. The total funding raised is reported to be between $6.39 million and $25.9 million across different data sources. PitchBook data indicates the company went out of business as of August 2018. Keywords: therapeutic devices, regenerative medicine, minimally invasive surgery, drug delivery systems, tissue engineering, hemostatic agents, fistula treatment, surgical powder, blood clotting, interventional devices, cell-based therapies, medical technology, vascular surgery, absorbable hemostat, surgical bleeding